Margaret Salisbury, MD
Pulmonary Disease · Nashville, TNNPI 1225359037
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 53.9% of the total. Reporting peaked in 2023 at $21,504 and has fallen 84.0% since, to $3,438 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $807.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$29K
- Boehringer Ingelheim$24K
- Genentech, Inc.$65
- Insmed, Inc.$32
Across 18 payments — averaging $16,736 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$178K
- GSK$114K
- Roche Products Limited$7K
- Hoffmann-la Roche Limited$2K
What the payments were for
- Consulting fees$25,00947%
- Speaking & faculty fees$9,49318%
- Travel & lodging$17,35333%
- Food & beverage$1,4093%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 9 | $28,720 |
| Boehringer Ingelheim | 54 | $24,480 |
| Genentech, Inc. | 1 | $65 |
| Insmed, Inc. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$35,643
How this compares
$53,297 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 130 | $1,530,582 |
| Pirfenidone | 56 | $174,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $18,705 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $16,521 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $7,669 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,043 |
| NexiumEsomeprazole Magnesium | 12 | $3,247 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,041 |
| Fluticasone Propionate | 34 | $733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $636 |
| Azelastine Hcl | 22 | $541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $24,480 | $1,530,582130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Karl KuhnNashville$106K
- Fabien MaldonadoNashville$83K
- Victor KhaNashville$44K
- Jennifer DukeNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.